WPC
RXRX icon

Wedmont Private Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Wedmont Private Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.4K Hold
18,943
– – ﹤0.01% 947
2026
Q1 		$64.2K Hold
18,943
– – ﹤0.01% 835
2025
Q4 		$92.1K Sell
18,943
-2,000
-10% -$9.91K ﹤0.01% 799
2025
Q3 		$110K Hold
20,943
– – ﹤0.01% 780
2025
Q2 		$117K Hold
20,943
– – 0.01% 731
2025
Q1 		$121K Hold
20,943
– – 0.01% 681
2024
Q4 		$144K Buy
20,943
+2,000
+11% +$13.4K 0.01% 683
2024
Q3 		$117K Hold
18,943
– – 0.01% 652
2024
Q2 		$158K Hold
18,943
– – 0.01% 620
2024
Q1 		$172K Buy
18,943
+2,000
+12% +$22.3K 0.01% 578
2023
Q4 		$214K Hold
16,943
– – 0.02% 513
2023
Q3 		$115K Hold
16,943
– – 0.01% 487
2023
Q2 		$202K Buy
+16,943
New +$119K 0.02% 474

Other funds holding RXRX

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
PL
Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $444M AUM 31.14% 1-Year Est. Return
NWMG
National Wealth Management Group Cincinnati, Ohio $323M AUM 39.23% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IIA
Integral Investment Advisors Turlock, California $454M AUM 21.42% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Wedmont Private Capital's RXRX Position: Q2 2026 in Review

Wedmont Private Capital held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 18,943 shares worth $67.4K. The position accounts for ﹤0.01% of the portfolio, ranked #947.

Wedmont Private Capital first reported a position in RXRX in Q2 2023 and has held it in 13 quarters since. The position peaked at $214K in Q4 2023. 24 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Wedmont Private Capital held 18,943 shares of Recursion Pharmaceuticals worth $67.4K as of Q2 2026.
  • Wedmont Private Capital left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Wedmont Private Capital's portfolio in Q2 2026, its #947 holding.
  • Wedmont Private Capital first reported a position in Recursion Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Wedmont Private Capital's Recursion Pharmaceuticals position peaked at $214K in Q4 2023.
  • 24 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Wedmont Private Capital's 13F filing for Q2 2026, filed 13 Jul 2026.